Key PointsQuestionHow did prices, market share, and spending on self-administered disease-modifying therapies for multiple sclerosis change in Medicare Part D from 2006 through 2016? FindingsThis cohort study found that between 2006 and 2016, the annual cost of treatment with self-administered disease-modifying therapies for multiple sclerosis more than quadrupled, from a mean of $18 660 to $75 847, increasing at a mean annual rate of 12.8%. Pharmaceutical spending per 1000 beneficiaries increased by 10.2-fold, from $7794 to $79 411, while out-of-pocket spending per 1000 beneficiaries increased by a factor of 7.2, from $372 to $2673. MeaningIn this study, prices of self-administered disease-modifying therapies for multiple sclerosis increased dramatically between 2006 and 2016, which resulted in a 7.2-fold increase in patients’ out-of-pocket costs.
JAMA Neurology – American Medical Association
Published: Nov 26, 2019
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera